Search Results
Keyword：targeted therapy
Department of Nuclear Medicine at Peking University First Hospital Receives EARL Theranostics Advanced-L2 Certification, Bringing Theranostics in Line with International Standards
The Department of Nuclear Medicine at Peking University First Hospital has recently officially received the Theranostics Advanced-L2 certification issued by EARL (EANM Research Ltd.), an affiliate of the European Association of Nuclear Medicine, becoming one of the few nuclear medicine theranostics centers in China to obtain this high-level certification. The certification audit standards are rigorous, covering comprehensive dimensions including PET/CT quantitative accuracy, therapy center operations, patient safety management, and clinical competency. Passing the certification means that the department's quantitative imaging and targeted therapy data meet internationally mutually recognized standards and can achieve high-level alignment with advanced nuclear medicine centers in Europe and the United States. During the certification review, EANM President-Elect Professor Felix M. Mottaghy and Ms. Iva...
2026-10-03
Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences
Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...
2026-08-07